Dr Cinzia Imberti is a UKRI Future Leaders Fellow and leads the Imaging Metallomics group at King’s College London.

Her group’s research aims to clarify pathways and behaviour of metal species – including both essential trace metals and metal-based (radio)pharmaceuticals – in cancer, by using a unique toolbox of multi-scale imaging techniques, such as Radionuclide Imaging, Synchrotron X-ray Absorption and Fluorescence (XAS and XRF) and Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS).

After completing her M.Sci degree in Chemistry at the University of Padova (Italy), Dr Imberti moved to the UK to undertake a MRes/PhD at King’s College London, working on the development of radiometal-based radiopharmaceuticals under the supervision of Prof. Phil Blower. In 2018, she was awarded a Sir Henry Wellcome Fellowship to study the mechanism of action of metal-based anticancer agents in the group of Prof. Peter Sadler (University of Warwick). In 2022, Dr Imberti joined Dr Jason Lewis’ group at Memorial Sloan Kettering Cancer Centre (New York) as a Research Associate investigating antibody-based imaging agents. In 2023 she moved to Bayer (Berlin) as a Research Scientist developing novel metal-based radiotherapies. In 2024, thanks to a UKRI FLF in Imaging Metallomics, Dr Imberti has returned to the Imaging Chemistry and Biology Department at King’s College London as a Group Leader.

Google scholar: https://scholar.google.com/citations?hl=it&user=a0Oyox0AAAAJ